Literature DB >> 28302714

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

Arief S Gunawan1, Donal P McLornan1, Bridget Wilkins1, Katherine Waghorn2, Yvette Hoade2, Nicholas C P Cross2, Claire N Harrison3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28302714      PMCID： PMC5451352          DOI： 10.3324/haematol.2017.163790

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature.

Authors:  M A Elliott; C A Hanson; G W Dewald; S A Smoley; T L Lasho; A Tefferi
Journal:  Leukemia       Date:  2005-02       Impact factor: 11.528

2.  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Authors:  Francisco Cervantes; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Andres Sirulnik; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard S Levy; Francesco Passamonti; Tiziano Barbui; Giovanni Barosi; Claire N Harrison; Laurent Knoops; Heinz Gisslinger
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

3.  Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease.

Authors:  J Böhm; H E Schaefer
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

4.  Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.

Authors:  T L Lasho; A Mims; M A Elliott; C Finke; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2014-01-21       Impact factor: 11.528

5.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Authors:  Rocco Piazza; Simona Valletta; Nils Winkelmann; Sara Redaelli; Roberta Spinelli; Alessandra Pirola; Laura Antolini; Luca Mologni; Carla Donadoni; Elli Papaemmanuil; Susanne Schnittger; Dong-Wook Kim; Jacqueline Boultwood; Fabio Rossi; Giuseppe Gaipa; Greta P De Martini; Paola Francia di Celle; Hyun Gyung Jang; Valeria Fantin; Graham R Bignell; Vera Magistroni; Torsten Haferlach; Enrico Maria Pogliani; Peter J Campbell; Andrew J Chase; William J Tapper; Nicholas C P Cross; Carlo Gambacorti-Passerini
Journal:  Nat Genet       Date:  2012-12-09       Impact factor: 38.330

Review 6.  The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.

Authors:  Jason Gotlib; Julia E Maxson; Tracy I George; Jeffrey W Tyner
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113

7.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors:  Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

8.  Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.

Authors:  Priya Koppikar; Neha Bhagwat; Outi Kilpivaara; Taghi Manshouri; Mazhar Adli; Todd Hricik; Fan Liu; Lindsay M Saunders; Ann Mullally; Omar Abdel-Wahab; Laura Leung; Abby Weinstein; Sachie Marubayashi; Aviva Goel; Mithat Gönen; Zeev Estrov; Benjamin L Ebert; Gabriela Chiosis; Stephen D Nimer; Bradley E Bernstein; Srdan Verstovsek; Ross L Levine
Journal:  Nature       Date:  2012-09-06       Impact factor: 49.962

9.  Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.

Authors:  Kim-Hien T Dao; Magdolna B Solti; Julia E Maxson; Elliott F Winton; Richard D Press; Brian J Druker; Jeffrey W Tyner
Journal:  Leuk Res Rep       Date:  2014-08-01
  9 in total
  17 in total

Review 1.  JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

2.  B-lymphoblastic leukemia arising in a patient with chronic neutrophilic leukemia.

Authors:  Craig S Boddy; Brent T Tan; Joseph Aoki
Journal:  Blood Adv       Date:  2020-11-10

3.  A t(1;9) translocation involving CSF3R as a novel mechanism in unclassifiable chronic myeloproliferative neoplasm.

Authors:  Jesús Gutiérrez-Abril; Iñigo Santamaría; Ana S Pitiot; Ana Gutiérrez-Fernández; Ángel Alvarez-Eguiluz; José M Vicente; Carmen Sanzo; Soledad González-Muñiz; Milagros Balbín; Xose S Puente
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

4.  Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia.

Authors:  Katherine Tarlock; Todd Alonzo; Yi-Cheng Wang; Robert B Gerbing; Rhonda E Ries; Tiffany Hylkema; Jenny L Smith; Julia E Maxson; Soheil Meshinchi
Journal:  Blood       Date:  2020-04-30       Impact factor: 22.113

5.  Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Authors:  Kim-Hien T Dao; Jason Gotlib; Michael M N Deininger; Stephen T Oh; Jorge E Cortes; Robert H Collins; Elliot F Winton; Dana R Parker; Hyunjung Lee; Anna Reister; Samantha Savage; Chase Brockett; Nan Subbiah; Richard D Press; Philipp W Raess; Michael Cascio; Jennifer Dunlap; Yiyi Chen; Catherine Degnin; Julia E Maxson; Cristina E Tognon; Tara Macey; Brian J Druker; Jeffrey W Tyner
Journal:  J Clin Oncol       Date:  2019-12-27       Impact factor: 44.544

Review 6.  Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Authors:  Kim-Hien T Dao; Jeffrey W Tyner; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

7.  Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis.

Authors:  S E Langabeer; K Haslam; J Kelly; J Quinn; R Morrell; E Conneally
Journal:  Clin Transl Oncol       Date:  2017-07-31       Impact factor: 3.405

Review 8.  Chronic neutrophilic leukemia: new science and new diagnostic criteria.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-13       Impact factor: 11.037

9.  CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.

Authors:  Natasha Szuber; Christy M Finke; Terra L Lasho; Michelle A Elliott; Curtis A Hanson; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-15       Impact factor: 11.037

Review 10.  Current Management of Chronic Neutrophilic Leukemia.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Curr Treat Options Oncol       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.